Form 4: Cytek Biosciences Director Converts Restricted Stock Units to Common Shares

Vera Imper, a Director at Cytek Biosciences, Inc., converted 15,706 Restricted Stock Units into an equal number of common shares on June 5, 2025, increasing her direct beneficial ownership.

Summary

• Vera Imper, a Director of Cytek Biosciences, Inc. (CTKB), reported a change in beneficial ownership of the company's securities.
• On June 5, 2025, Ms. Imper acquired 15,706 shares of common stock through the conversion of Restricted Stock Units (RSUs).
• The transaction code 'M' indicates a conversion or exercise of derivative securities.
• Following this transaction, Ms. Imper directly beneficially owns 15,706 shares of common stock.
• The Restricted Stock Units (RSU Award) represented a contingent right to receive one share of the Issuer's common stock.
• 100% of the shares subject to the RSU Award vested on June 5, 2025, leading to the conversion.

Sentiment

Score: 6

Explanation: The filing indicates a routine vesting and conversion of equity compensation for a director, leading to an increase in direct beneficial ownership. This is generally a neutral to slightly positive event as it aligns director interests with shareholders, but it does not convey new strategic or financial performance information.

Positives

• The transaction indicates a director increasing their direct beneficial ownership in the company, which can be viewed as a positive sign of alignment with shareholder interests.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders may view the increase in direct ownership by a director as a positive sign of alignment between management and shareholder interests.

Key Dates

Keywords

Cytek Biosciences, CTKB, Form 4, SEC filing, insider trading, beneficial ownership, restricted stock units, RSU, stock vesting, director ownership